Sep 08, 2023 / NTS GMT
Manny Anton - ShareCafe - Moderator
Next up, we have Antisense Therapeutics. The ASX code is ANP. Antisense have a market cap of around 57 million. Antisense Therapeutics is a biotechnology company developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. We welcome newly appointed Antisense CEO, Dr. James Garner. James, take it away.
James Garner - Antisense Therapeutics Limited - CEO
Thanks so much, Manny. It's great to be here today and really a wonderful opportunity to introduce the company to investors. If you jump ahead maybe a couple of slides, please. I'm going to jump straight in here, change of gear from the previous presentations. One more slide on please.
And I'm going to introduce the disease area that our company is focused on. As Manny mentioned at the top of the presentation, we're a biotech company, we're focused on developing new medicines, and in particular, we're focused on a disease area called Duchenne muscular dystrophy. And this is a genetic illness that affects almost exclusively boys. And so
Antisense Therapeutics Ltd at ShareCafe Hidden Gems Webinar Transcript
Sep 08, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers